Gillian McGovern, Editor

The intervention methods—annual asthma reviews, inhaler technique checks, and asthma management plans—were most effective when performed in the same visit.

The data also shows similar results for children with mothers who have pre-pregnancy body mass index outside of normal range.

Participants who completed the curriculum had answered 82% of the post-test correctly.

The study found that this patient population was about 25% more likely to have serious mental health issues after childbirth.

The analysis also found that the intervention methods could improve patients’ physical, cognitive, and emotional functioning.

Among this population, about 80% had not previously been diagnosed with asthma and over 30% were not using any asthma medications.

For up to 6 years, cognitive remediation and transcranial direct current stimulation slowed cognitive decline associated with major depressive disorder in remission and mild cognitive impairment.

The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.

Patients with low-grade intermediate-risk non-muscle-invasive bladder cancer who achieved a complete response rate after 3 months of UGN-102 treatment had an 82.3% duration of response at 12 months.

The findings show robust connections between symptoms, with variations in depression scores directly or indirectly influence fatigue and other symptoms.

The results found that women, non-binary, and sexual minority students are at the highest risk.

Using in vitro models, study investigators predict the risk of bone metastasis in breast cancer based on correlations with their in vivo behaviors and potential.

About 41% and 30% of patients with chronic spontaneous urticaria (CSU), respectively, achieved well-controlled disease status and complete response when treated with dupilumab.

The approval comes after the phase 3 clinical trials MVOR-1 (NCT05296629) and MVOR-2 (NCT05343455).

At weeks 16 and 24, approximately 57% and 60% of patients with moderate to severe atopic dermatitis, respectively, achieved at least 75% improvement in Eczema Area and Severity Index score.

Compared with a short-acting β agonist (SABA) alone, inhaled corticosteroids (ICS) with formoteral and ICS with a SABA were associated with better asthma control.

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).

This model, which uses technology that discovers black holes, pulls from real data to evaluate cancer treatments, optimizing treatment choices for patients with different cancers.

The accelerated approval comes after 48-week major molecular response rate data.

The investigators found that the SRGAP2 and SYNGAP1 genes act together to control the speed of human synapse development, which has impacts on neurodevelopmental disease pathways.

Pregnancy rtes show similarity across the different glucagon-like peptide-1 (GLP-1) medications that were prescribed.

The investigators note that these findings are significant because bile duct cancer is a rare disease with limited treatments and low survival rates.

The authors note that exercise beyond 3 times per week was not associated with a lower risk of asthma, and more research is needed to confirm this finding.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

In postmenopausal women, the gel can reduce moderate to severe hot flashes as well as menopausal changes and symptoms.

NCCN recommends ribociclib as a preferred CDK4/6 inhibitor adjuvant therapy for patients with HR+/HER2- EBC in combination with an aromatase inhibitor.

Congenital muscular dystrophy type 1a is a severe, early-onset condition that currently has no treatment, but MDL-101 may serve as a 1-time, durable treatment option.

The FDA announces a Class II recall for the lot #220128, which were reported to contain the presence of nitrosamine.